Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE-/- Mice

Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):491-500. doi: 10.1161/ATVBAHA.115.307057. Epub 2016 Jan 28.

Abstract

Objective: Inflammatory monocytes/macrophages produce various proteinases, including matrix metalloproteinases, and degradation of the extracellular matrix by these activated proteinases weakens the mechanical strength of atherosclerotic plaques, which results in a rupture of the plaque. Peroxisome proliferator-activated receptor-γ induces a polarity shift of monocytes/macrophages toward less inflammatory phenotypes and has the potential to prevent atherosclerotic plaque ruptures. Therefore, we hypothesized that nanoparticle-mediated targeted delivery of the peroxisome proliferator-activated receptor-γ agonist pioglitazone into circulating monocytes could effectively inhibit plaque ruptures in a mouse model.

Approach and results: We prepared bioabsorbable poly(lactic-co-glycolic-acid) nanoparticles containing pioglitazone (pioglitazone-NPs). Intravenously administered poly(lactic-co-glycolic-acid) nanoparticles incorporated with fluorescein isothiocyanate were found in circulating monocytes and aortic macrophages by flow cytometric analysis. Weekly intravenous administration of pioglitazone-NPs (7 mg/kg per week) for 4 weeks decreased buried fibrous caps, a surrogate marker of plaque rupture, in the brachiocephalic arteries of ApoE(-/-) mice fed a high-fat diet and infused with angiotensin II. In contrast, administration of control-NPs or an equivalent dose of oral pioglitazone treatment produced no effects. Pioglitazone-NPs inhibited the activity of matrix metalloproteinases and cathepsins in the brachiocephalic arteries. Pioglitazone-NPs regulated inflammatory cytokine expression and also suppressed the expression of extracellular matrix metalloproteinase inducer in bone marrow-derived macrophages.

Conclusions: Nanoparticle-mediated delivery of pioglitazone inhibited macrophage activation and atherosclerotic plaque ruptures in hyperlipidemic ApoE(-/-) mice. These results demonstrate a promising strategy with a favorable safety profile to prevent atherosclerotic plaque ruptures.

Keywords: macrophages; matrix metalloproteinases; nanoparticles; pioglitazone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous
  • Angiotensin II
  • Animals
  • Apolipoproteins E / deficiency
  • Apolipoproteins E / genetics
  • Atherosclerosis / chemically induced
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / genetics
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Brachiocephalic Trunk / drug effects
  • Brachiocephalic Trunk / metabolism
  • Brachiocephalic Trunk / pathology
  • Cardiovascular Agents / administration & dosage
  • Cardiovascular Agents / chemistry
  • Cardiovascular Agents / pharmacology*
  • Cathepsins / metabolism
  • Cell Differentiation / drug effects*
  • Cells, Cultured
  • Chemistry, Pharmaceutical
  • Cytokines / metabolism
  • Diet, High-Fat
  • Disease Models, Animal
  • Disease Progression
  • Drug Carriers*
  • Inflammation Mediators / metabolism
  • Lactic Acid / chemistry*
  • Macrophages, Peritoneal / drug effects*
  • Macrophages, Peritoneal / metabolism
  • Macrophages, Peritoneal / pathology
  • Male
  • Matrix Metalloproteinases / metabolism
  • Mice, 129 Strain
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Monocytes / drug effects*
  • Monocytes / metabolism
  • Monocytes / pathology
  • Nanoparticles*
  • Phenotype
  • Pioglitazone
  • Plaque, Atherosclerotic*
  • Polyglycolic Acid / chemistry*
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Rupture, Spontaneous
  • Thiazolidinediones / administration & dosage
  • Thiazolidinediones / chemistry
  • Thiazolidinediones / pharmacology*

Substances

  • Apolipoproteins E
  • Cardiovascular Agents
  • Cytokines
  • Drug Carriers
  • Inflammation Mediators
  • Thiazolidinediones
  • Angiotensin II
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Cathepsins
  • Matrix Metalloproteinases
  • Pioglitazone